Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Exelixis PLK4 compound 25
- Development stage
- Preclinical
- Lead developer
- Exelixis
01
Overview
Exelixis PLK4 compound 25: sourced facts only. name: "Herein, we disclose the discovery of 25, a potent and selective PLK4 inhibitor." [PMID:41329867]; target: "Herein, we disclose the discovery of 25, a potent and selective PLK4 inhibitor." [PMID:41329867]; developer: "Small Molecule Discovery, Exelixis, Inc., 1851 Harbor Bay Parkway, Alameda, California 94502, United States." [PMID:41329867]; stage: "Tumor regression was observed in efficacy studies of compound 25 in a CHP-134 neuroblastoma xenograft tumor model." [PMID:41329867]
02
Targets
PLK4 (Polo-like kinase 4)
Beyond the preview
Go deeper on Exelixis PLK4 compound 25.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exelixis PLK4 compound 25.